Literature DB >> 19925419

Current clinical applications of botulinum toxin.

Daniel D Truong1, Andrea Stenner, Gerhard Reichel.   

Abstract

Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925419     DOI: 10.2174/138161209789271843

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

Review 1.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

2.  Targeting botulinum A cellular toxicity: a prodrug approach.

Authors:  Peter Silhár; Lisa M Eubanks; Hajime Seki; Sabine Pellett; Sacha Javor; William H Tepp; Eric A Johnson; Kim D Janda
Journal:  J Med Chem       Date:  2013-10-15       Impact factor: 7.446

3.  Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.

Authors:  Christina L Pier; Chen Chen; William H Tepp; Guangyun Lin; Kim D Janda; Joseph T Barbieri; Sabine Pellett; Eric A Johnson
Journal:  FEBS Lett       Date:  2010-11-30       Impact factor: 4.124

Review 4.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 5.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

6.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

7.  Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin.

Authors:  Kavitha Mukund; Margie Mathewson; Viviane Minamoto; Samuel R Ward; Shankar Subramaniam; Richard L Lieber
Journal:  Muscle Nerve       Date:  2014-03-17       Impact factor: 3.217

Review 8.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

9.  Obturator nerve block with botulinum toxin type B for patient with adductor thigh muscle spasm -a case report-.

Authors:  Eun Joo Choi; Jong Min Byun; Francis Sahngun Nahm; Pyung Bok Lee
Journal:  Korean J Pain       Date:  2011-09-06

10.  Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin A1.

Authors:  Jean Mukherjee; Chase McCann; Kwasi Ofori; Julia Hill; Karen Baldwin; Charles B Shoemaker; Peter Harrison; Saul Tzipori
Journal:  Toxins (Basel)       Date:  2012-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.